# Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

> **NCT04652570** · PHASE1,PHASE2 · TERMINATED · sponsor: **Tenet Medicines** · enrollment: 6 (actual)

## Conditions studied

- Membranous Nephropathy

## Interventions

- **DRUG:** VB119

## Key facts

- **NCT ID:** NCT04652570
- **Lead sponsor:** Tenet Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-05
- **Primary completion:** 2023-11-21
- **Final completion:** 2024-08-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor change
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04652570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04652570, "Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04652570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*